<?xml version="1.0" encoding="UTF-8"?>
<ref id="B186-marinedrugs-17-00374" class="ref">
 <label class="label">186.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Fletcher</surname>
    <given-names class="given-names">E.L.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Wang</surname>
    <given-names class="given-names">A.Y.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Jobling</surname>
    <given-names class="given-names">A.I.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Rutar</surname>
    <given-names class="given-names">M.V.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Greferath</surname>
    <given-names class="given-names">U.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Gu</surname>
    <given-names class="given-names">B.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Vessey</surname>
    <given-names class="given-names">K.A.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Targeting P2X7 receptors as a means for treating retinal disease</article-title>
  <source class="source">Drug Discov. Today</source>
  <year class="year">2019</year>
  <pub-id pub-id-type="doi" class="pub-id">10.1016/j.drudis.2019.03.029</pub-id>
  <?supplied-pmid 30954685?>
  <pub-id pub-id-type="pmid" class="pub-id">30954685</pub-id>
 </element-citation>
</ref>
